An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

A recent award ceremony which is actually significant revealed about the best companies right now existing in the country US ...

The poultry medicine/pharmaceuticals market valued at US$ 4.73 billion in 2023, is forecasted to grow at a robust CAGR of 5.9%, reaching US$ ...

Global Capability Centers — offshore units that handle the parent’s business processes — accounted for over a third of the ...